AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors (NASDAQ:AZN)

Group 1 - AstraZeneca's share price has increased by 6% over the past four months since the last analysis [1] - The article highlights AstraZeneca as potentially being one of the most underrated pharmaceutical stocks for 2025 [1] Group 2 - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including pharmaceuticals [2] - The firm aims to simplify investment strategies and empower both seasoned and novice investors [2] - Allka Research contributes analyses and insights to the Seeking Alpha community, fostering informed investment decisions [2]